Mankind Pharma Sees Sharp Open Interest Surge Amid Strong Derivatives Activity

Open Interest Spike and Volume Dynamics

The latest data reveals that Mankind Pharma’s open interest (OI) in derivatives jumped sharply by 8,172 contracts, a 38.78% increase from the previous figure of 21,071 to 29,243. This substantial rise in OI is accompanied by a robust volume of 1,17,848 contracts traded, underscoring active positioning by market participants. The futures segment alone accounted for a value of approximately ₹20,075 lakhs, while options contributed an overwhelming ₹70,201.94 crores, culminating in a total derivatives value of ₹27,902.42 lakhs.

This surge in OI, combined with elevated volumes, typically indicates fresh capital inflows and new positions being established rather than mere unwinding of existing trades. Such a pattern often precedes significant price movements, as traders and investors recalibrate their exposure based on evolving market outlooks.

Price Performance and Technical Strength

On the price front, Mankind Pharma has demonstrated strong momentum. The stock gained 5.98% in a single day, substantially outperforming the Pharmaceuticals & Biotechnology sector’s 1.15% rise and the Sensex’s modest 0.36% advance. Notably, the stock opened with a gap up of 5.89% and touched an intraday high of ₹2,436.90, representing a 5.92% increase from the previous close.

Over the past three consecutive trading sessions, Mankind Pharma has delivered an impressive 8.5% return, reflecting sustained buying interest. The stock is currently trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a strong uptrend and technical resilience. The narrow intraday trading range of ₹0.8 suggests consolidation near highs, often a precursor to further directional moves.

Investor Participation and Liquidity Considerations

Investor engagement has also intensified, with delivery volumes reaching 3.72 lakh shares on 18 September, marking a 23.62% increase over the five-day average delivery volume. This rise in delivery volume indicates genuine accumulation rather than speculative trading, reinforcing the bullish sentiment.

Liquidity remains adequate for sizeable trades, with the stock’s average traded value supporting transactions up to ₹2.51 crore based on 2% of the five-day average. This level of liquidity is favourable for institutional investors and traders seeking to build or exit positions without significant market impact.

Market Positioning and Directional Bets

The pronounced increase in open interest alongside rising prices and volumes suggests that market participants are positioning for further upside in Mankind Pharma. The stock’s mojo score currently stands at 50.0 with a mojo grade of Hold, reflecting a cautious stance after a recent downgrade from Buy on 3 August 2026. Despite this, the recent price action and derivatives activity indicate renewed optimism among traders.

Given the stock’s mid-cap status with a market capitalisation of ₹98,536 crore, it attracts a blend of institutional and retail interest. The pharmaceutical sector’s defensive qualities combined with Mankind Pharma’s improving fundamentals and technical strength make it a compelling candidate for directional bets, particularly in the derivatives market where leverage amplifies potential gains.

Comparative Sector and Index Performance

Outperforming the sector by 4.8% on the day, Mankind Pharma’s relative strength is notable. The Pharmaceuticals & Biotechnology sector has been under moderate pressure recently, making this stock’s resilience stand out. The Sensex’s marginal 0.36% gain further highlights Mankind Pharma’s leadership within its industry group.

Such outperformance often attracts momentum traders and can trigger additional buying interest, especially when supported by strong open interest growth and volume expansion in the derivatives segment.

Outlook and Investor Takeaways

While the mojo grade downgrade to Hold signals some caution, the recent surge in open interest and volume, coupled with strong price action, suggests that Mankind Pharma remains in a favourable technical position. Investors should monitor whether the stock can sustain its momentum above key moving averages and maintain rising delivery volumes, which would confirm genuine accumulation.

Given the pharmaceutical sector’s defensive appeal amid broader market uncertainties, Mankind Pharma’s mid-cap status and improving market positioning could attract further interest. However, investors should remain vigilant for any sector-wide headwinds or profit-booking that could temper gains.

In summary, the derivatives market activity points to increased bullish bets on Mankind Pharma, supported by solid fundamentals and technical strength. This combination makes the stock a noteworthy candidate for investors seeking exposure to the Pharmaceuticals & Biotechnology sector with a balanced risk-reward profile.

Company Snapshot

Mankind Pharma Ltd operates within the Pharmaceuticals & Biotechnology industry and is classified as a mid-cap company with a market capitalisation of ₹98,536 crore. The stock’s recent performance and derivatives market activity highlight its growing prominence among investors and traders alike.

Key Metrics Summary

Latest Open Interest: 29,243 contracts (up 38.78%)
Volume: 1,17,848 contracts
Futures Value: ₹20,074.99 lakhs
Options Value: ₹70,201.94 crores
Total Derivatives Value: ₹27,902.42 lakhs
Underlying Price: ₹2,435
1-Day Return: 5.98%
Sector 1-Day Return: 1.15%
Sensex 1-Day Return: 0.36%
Mojo Score: 50.0 (Hold, downgraded from Buy on 3 Aug 2026)

Conclusion

The sharp increase in open interest and volume in Mankind Pharma’s derivatives signals a clear shift in market sentiment towards a more bullish stance. Supported by strong price gains and rising investor participation, the stock is poised for potential further upside. However, the Hold mojo grade advises measured optimism, suggesting investors should keep a close watch on evolving market conditions and sector dynamics before committing significant capital.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →